Compass Therapeutics (CMPX) Investor Presentation - Slideshow

Corporate Strategy & Resources - Compass Therapeutics is a clinical-stage biotech company focused on developing antibody therapeutics for cancer[6] - The company's cash runway extends into 2026, with $120 million in cash and marketable securities as of September 2022, plus an $80 million PIPE in November 2022[6] CTX-009 (DLL4 x VEGF-A Bispecific Antibody) - Phase 1a monotherapy showed clinical activity at RP2D dosages (10 and 12.5 mg/kg), with a 19% partial response (PR) rate and a 69% clinical benefit rate (PR + SD) in all patients (n=16)[15] - In a Phase 1b combination study, cholangiocarcinoma patients showed a 50% overall response rate (ORR) and a 75% clinical benefit rate, with a median duration of response of 9.7 months[13] - Interim Phase 2 data in biliary tract cancers (BTC) showed a 42% ORR and a 92% clinical benefit rate (CBR) in patients treated in the second- and third-line settings[38, 54] - A Phase 2/3 randomized BTC study in the US is planned, randomizing 80 patients to CTX-009 + Paclitaxel vs 40 patients to Paclitaxel[55] CTX-471 (CD137 Agonist Antibody) - Phase 1 monotherapy study showed 4 partial responses (PRs) in post PD-1 population: small cell lung cancer, metastatic melanoma, mucosal melanoma, mesothelioma[64, 80] - A Phase 1b study of CTX-471 in combination with Keytruda® (anti-PD-1 therapy) is planned[67] CTX-8371 (PD-1 x PD-L1 Bispecific Antibody) - Preclinical studies showed superior activity to commercial PD-1 and PD-L1 inhibitors, with a unique mechanism of action enhancing T-cell activation[69, 80] - IND submission is targeted for H1 2023[79]